BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $878 | -20.2% | 12,647 | -3.7% | 0.02% | -16.7% |
| Q2 2023 | $1,100 | +1.2% | 13,136 | -10.3% | 0.02% | -7.7% |
| Q1 2023 | $1,087 | +16.9% | 14,644 | +30.6% | 0.03% | +13.0% |
| Q4 2022 | $930 | -99.8% | 11,216 | +437.9% | 0.02% | +43.8% |
| Q3 2022 | $592,000 | -17.1% | 2,085 | +1.3% | 0.02% | -15.8% |
| Q2 2022 | $714,000 | -11.2% | 2,058 | +10.8% | 0.02% | +5.6% |
| Q1 2022 | $804,000 | -19.0% | 1,858 | -3.1% | 0.02% | -18.2% |
| Q4 2021 | $992,000 | -56.0% | 1,918 | -58.7% | 0.02% | -58.5% |
| Q3 2021 | $2,252,000 | +26.9% | 4,648 | +17.9% | 0.05% | +26.2% |
| Q2 2021 | $1,775,000 | +8.8% | 3,943 | -7.7% | 0.04% | +5.0% |
| Q1 2021 | $1,632,000 | +18.3% | 4,273 | -1.6% | 0.04% | +14.3% |
| Q4 2020 | $1,379,000 | +30.2% | 4,343 | +1.6% | 0.04% | +16.7% |
| Q3 2020 | $1,059,000 | -2.9% | 4,273 | +3.4% | 0.03% | -6.2% |
| Q2 2020 | $1,091,000 | +47.8% | 4,133 | +6.2% | 0.03% | +23.1% |
| Q1 2020 | $738,000 | -11.8% | 3,893 | +2.1% | 0.03% | +13.0% |
| Q4 2019 | $837,000 | +26.6% | 3,813 | +12.8% | 0.02% | +21.1% |
| Q3 2019 | $661,000 | -10.4% | 3,380 | -4.5% | 0.02% | -9.5% |
| Q2 2019 | $738,000 | +2.2% | 3,541 | -2.6% | 0.02% | +5.0% |
| Q1 2019 | $722,000 | +45.9% | 3,635 | +6.2% | 0.02% | +33.3% |
| Q4 2018 | $495,000 | -57.6% | 3,423 | -40.2% | 0.02% | -50.0% |
| Q3 2018 | $1,168,000 | +11.7% | 5,723 | -19.1% | 0.03% | +7.1% |
| Q2 2018 | $1,046,000 | -0.1% | 7,070 | +2.0% | 0.03% | +3.7% |
| Q1 2018 | $1,047,000 | -4.1% | 6,930 | -17.8% | 0.03% | +3.8% |
| Q4 2017 | $1,092,000 | +7.3% | 8,430 | +0.1% | 0.03% | 0.0% |
| Q3 2017 | $1,018,000 | 0.0% | 8,420 | 0.0% | 0.03% | 0.0% |
| Q3 2016 | $1,018,000 | – | 8,420 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |